Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma

Jin, Young–Joo; Lee, Han Chu; Lee, Danbi; Shim, Ju Hyun; Kim, Kang Mo; Lim, Young‐Suk; Do, Kyung-Hyun; Ryu, Jin Sook

doi:10.1016/j.jhep.2011.12.027

Cited by 17 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13 These reports did not correlate the disease progression in the abdomen with the progression of the disease in the chest. 7,[9][10][11][12] In the present study, baseline CT revealed a prevalence (76/226; 33.6%) of extrahepatic metastatic disease at baseline. The incidence of extrahepatic disease in the present study (33.6%) was larger than that reported previously.…”

Section: Discussionmentioning

confidence: 65%

“…8 Jin et al, evaluating the role of chest CT in the staging workup of HCC patients, found that 2.9% of patients had metastatic disease in the chest but not the liver. 11 Others have also reported a limited role of the chest CT examination in HCC patients. 12,13 These reports did not correlate the disease progression in the abdomen with the progression of the disease in the chest.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of extrahepatic disease in the present study (33.6%) was larger than that reported previously. 7,[9][10][11][12] This may have been because our study was conducted at a tertiary cancer center, whose patients tend to have more advanced disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma</p>

Moawad¹,

Elsayes²,

Benamar³

et al. 2020

JHC

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma</p>

Moawad¹,

Elsayes²,

Benamar³

et al. 2020

JHC

View full text Add to dashboard Cite

“…Our study assessed a smaller number compared to the study by Rodriguez et al but the total number of BSs was larger as our patients had repeat BS every 6 months while on the LTx. Data regarding staging of early-HCC patients before surgical resection 17,21 and on initial staging for new diagnosis of HCC 22 confirm the low diagnostic yield of BS in early-stage HCC.…”

Section: Discussionmentioning

confidence: 83%

Value of Bone Scans in Work-up of Patients With Hepatocellular Carcinoma for Liver Transplant

Kutaiba

Ardalan

Patwala

et al. 2018

Transplantation Direct

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to review the value of bone scans (BS) in the assessment of bone metastases from early-stage hepatocellular carcinoma (HCC) in patients assessed or waiting for liver transplant (LTx).MethodsWe reviewed BS studies performed at our center for patients with early-stage HCC either being assessed for LTx, or on the waiting list for LTx, from January 2010 to May 2017. The BS findings were classified as positive, equivocal, or negative. Correlation with final outcome based on clinical and radiological follow-up was performed.ResultsThere were 360 BS performed in 186 patients during the study period with a mean age of 58.7 years (range, 34.9-70.4 years) and most were male patients (161/186 [86.6%]). None of the BSs resulted in delisting of patients from the LTx waiting list. Three BSs were reported as positive for metastases. All 3 were proven to be false positives on follow-up. Fourteen studies reported equivocal findings, none of which were confirmed to be metastases on follow-up. There was 1 false-negative BS: a bone metastasis was detected incidentally on magnetic resonance imaging and proven on biopsy.ConclusionsWe have demonstrated that the diagnostic yield of BS in early HCC patients who are candidates for LTx is minimal, challenging the current inclusion of BS in guidelines for staging these HCC patients.

show abstract

“…CT provides optimal information in the staging of the abdomen and thorax. In a prospective clinical study the routine use of chest CT and bone scan did not provide additional information on metastases in HCC patients with BCLC 0, A, C or D stages and led to a stage shift from BCLC B to C in about 5% of patients [29]. …”

Section: Stagingmentioning

confidence: 99%

Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment

Schütte

Schulz

Malfertheiner

2014

Gastrointest Tumors

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) significantly contributes to the global burden of cancer. Liver cancer is the third most frequent cause of cancer-related death, with HCC representing more than 90% of primary liver cancers. During the last decade, much progress has been made with respect to the definition of patient populations at risk who may benefit from surveillance strategies, as well as in the diagnosis and treatment of the disease. Summary: New locoregional and systemic therapies have significantly increased the survival of patients with HCC. A multitude of clinical trials addressing patients with HCC have led to advancements in the allocation of subgroups of patients to their optimal individual treatment strategy. This review provides an overview on recent developments in diagnostic and therapeutic modalities and an outlook on future directions in the management of HCC. Key Message: New locoregional and systemic therapies in patients with HCC have significantly improved clinical outlook and patient survival. This review provides an overview of recent developments in diagnostics and therapeutics, as well as an outlook on future directions in the management of HCC. Practical Implications: Transabdominal ultrasound is the method of choice for the surveillance of patients at risk of developing HCC, and any suspicious focal lesion in the liver should be characterized. Contrast-enhanced ultrasound with application of second-generation contrast agents enables visualization of tumor vascularity. The Barcelona Clinic Liver Cancer (BCLC) system is the most widely used classification system to guide the clinical management of HCC. Liver resection should be considered for patients with well-preserved liver function and without portal hypertension or elevated bilirubin. Patients not suitable for resection should undergo local tumor ablation. Candidates who are eligible for liver transplantation may benefit from bridging therapy during their waiting period. Patients in the BCLC B category benefit from locoregional transarterial therapy; transarterial chemoembolization is the treatment of choice. Sorafenib is the only systemic therapy that has been shown to prolong overall survival in patients with advanced disease, and is therefore recommended in patients with well-preserved liver function.

show abstract

Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma

Cited by 17 publications

References 21 publications

<p>Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma</p>

<p>Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma</p>

Value of Bone Scans in Work-up of Patients With Hepatocellular Carcinoma for Liver Transplant

Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment

Contact Info

Product

Resources

About